Targeted therapy of cancer: new roles for pathologists in colorectal cancer

[1]  A. Russo,et al.  Pharmacogenomics in colorectal carcinomas: Future perspectives in personalized therapy , 2005, Journal of cellular physiology.

[2]  D. Arnold,et al.  Update on capecitabine in colorectal cancer. , 2006, The oncologist.

[3]  A. Benson.  New approaches to the adjuvant therapy of colon cancer. , 2006, The oncologist.

[4]  Patrick G Johnston,et al.  Have we made progress in pharmacogenomics? The implementation of molecular markers in colon cancer. , 2005, Pharmacogenomics.

[5]  J. Treluyer,et al.  Pharmacogenomics of Fluorouracil, Irinotecan, and Oxaliplatin in Hepatic Metastases of Colorectal Cancer , 2005, American journal of pharmacogenomics : genomics-related research in drug development and clinical practice.

[6]  S. Groshen,et al.  Molecular determinants of cetuximab efficacy. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[7]  Daniel F Hayes,et al.  ASCO 2006 update of recommendations for the use of tumor markers in gastrointestinal cancer. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[8]  I. Endo,et al.  Predicting 5‐fluorouracil chemosensitivity of liver metastases from colorectal cancer using primary tumor specimens: Three‐gene expression model predicts clinical response , 2006, International journal of cancer.

[9]  Young Bae Kim,et al.  Which Gene is a Dominant Predictor of Response During FOLFOX Chemotherapy for the Treatment of Metastatic Colorectal Cancer, the MTHFR or XRCC1 Gene? , 2006, Annals of Surgical Oncology.

[10]  V. Catalano,et al.  Pharmacogenetic profiling in patients with advanced colorectal cancer treated with first-line FOLFOX-4 chemotherapy. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[11]  S. Groshen,et al.  Colorectal tumors responding to 5-fluorouracil have low gene expression levels of dihydropyrimidine dehydrogenase, thymidylate synthase, and thymidine phosphorylase. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

[12]  F. Pruvot,et al.  Lack of usefulness of epidermal growth factor receptor expression determination for cetuximab therapy in patients with colorectal cancer , 2006, Anti-cancer drugs.

[13]  J. Marshall.  The role of bevacizumab as first-line therapy for colon cancer. , 2005, Seminars in oncology.

[14]  A. Pallis,et al.  Adjuvant chemotherapy for colon cancer. , 2006, Anticancer research.

[15]  New Trends in Cancer for the 21st Century , 2003, Advances in Experimental Medicine and Biology.

[16]  Silvia Benvenuti,et al.  Gene copy number for epidermal growth factor receptor (EGFR) and clinical response to antiEGFR treatment in colorectal cancer: a cohort study. , 2005, The Lancet. Oncology.

[17]  A. Benson.  Adjuvant chemotherapy of stage III colon cancer. , 2005, Seminars in oncology.

[18]  A. Abad,et al.  Combined analysis of genetic polymorphisms in thymidylate synthase, uridine diphosphate glucoronosyltransferase and X-ray cross complementing factor 1 genes as a prognostic factor in advanced colorectal cancer patients treated with 5-fluorouracil plus oxaliplatin or irinotecan. , 2007, Oncology reports.

[19]  F. Ahmed.  Molecular markers that predict response to colon cancer therapy , 2005, Expert review of molecular diagnostics.

[20]  C. Nadal,et al.  FAS/FAS Ligand Ratio: A Marker of Oxaliplatin-Based Intrinsic and Acquired Resistance in Advanced Colorectal Cancer , 2005, Clinical Cancer Research.

[21]  J. Meyerhardt,et al.  Impact of physical activity on cancer recurrence and survival in patients with stage III colon cancer: findings from CALGB 89803. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[22]  M. Fukushima,et al.  Upregulation of Enzymes Metabolizing 5-Fluorouracil in Colorectal Cancer , 2006, Chemotherapy.

[23]  Ashley N. Tran,et al.  Pharmacogenomics of Colorectal Cancer Prevention and Treatment , 2006, Cancer investigation.

[24]  J. Grem.  Intratumoral molecular or genetic markers as predictors of clinical outcome with chemotherapy in colorectal cancer. , 2005, Seminars in oncology.

[25]  R. Houlston,et al.  Systematic review of microsatellite instability and colorectal cancer prognosis. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[26]  M. Moroni,et al.  Epidermal growth factor receptor gene copy number and clinical outcome of metastatic colorectal cancer treated with panitumumab. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[27]  A. Jubb,et al.  Association of k-ras, b-raf, and p53 status with the treatment effect of bevacizumab. , 2005, Journal of the National Cancer Institute.

[28]  Ivan Brandslund,et al.  Epidermal growth factor receptor analyses in colorectal cancer: a comparison of methods. , 2006, International journal of oncology.

[29]  B. Iacopetta.  Methyl-group metabolism and the response of colorectal cancer to 5-fluorouracil. , 2006, Critical reviews in oncogenesis.

[30]  W. Demark-Wahnefried.  Cancer survival: time to get moving? Data accumulate suggesting a link between physical activity and cancer survival. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[31]  E. Díaz-Rubio.  Vascular endothelial growth factor inhibitors in colon cancer. , 2006, Advances in experimental medicine and biology.

[32]  S. Madhusudan,et al.  Current status of excision repair cross complementing-group 1 (ERCC1) in cancer. , 2007, Cancer treatment reviews.

[33]  A. V. van Kuilenburg,et al.  Screening for Dihydropyrimidine Dehydrogenase Deficiency: To Do or Not To Do, That's The Question , 2006, Cancer investigation.

[34]  K. Holen.  Target Practice: Figuring Out Which, When, and Why to Use Systemic Therapies for Metastatic Colon Cancer , 2006, Cancer investigation.

[35]  M. Camilleri,et al.  Clinical application of pharmacogenetics in gastrointestinal diseases , 2006, Expert opinion on pharmacotherapy.

[36]  T. Eberlein.  Lymph Node Status and TS Gene Expression Are Prognostic Markers in Stage II/III Rectal Cancer After Neoadjuvant Fluorouracil-Based Chemoradiotherapy , 2008 .

[37]  D. Cunningham,et al.  Adjuvant therapy in colon cancer--what, when and how? , 2006, Annals of oncology : official journal of the European Society for Medical Oncology.

[38]  C. Pinto,et al.  Does biomolecular characterization of stage II/III colorectal cancer have any prognostic value? , 2006, Clinical colorectal cancer.

[39]  J. Hecht,et al.  Panitumumab in colon cancer: a review and summary of ongoing trials , 2006, Expert opinion on biological therapy.

[40]  G. La Torre,et al.  Predictive Role of Thymidylate Synthase, Dihydropyrimidine Dehydrogenase and Thymidine Phosphorylase Expression in Colorectal Cancer Patients Receiving Adjuvant 5-Fluorouracil , 2007, Oncology.

[41]  New approaches to the adjuvant therapy of colon cancer. , 2006, The oncologist.

[42]  S. Groshen,et al.  ERCC1 gene polymorphism as a predictor for clinical outcome in advanced colorectal cancer patients treated with platinum-based chemotherapy. , 2003, Clinical advances in hematology & oncology : H&O.

[43]  U. Fuhr,et al.  How may Anticancer Chemotherapy with Fluorouracil be Individualised? , 2006, Clinical pharmacokinetics.

[44]  P. Jänne,et al.  EGFR FISH assay predicts for response to cetuximab in chemotherapy refractory colorectal cancer patients. , 2008, Annals of oncology : official journal of the European Society for Medical Oncology.

[45]  J. García-Foncillas,et al.  Polymorphisms in the thymidylate synthase and dihydropyrimidine dehydrogenase genes predict response and toxicity to capecitabine-raltitrexed in colorectal cancer. , 2007, Oncology reports.

[46]  A. Italiano,et al.  Cetuximab Shows Activity in Colorectal Cancer Patients With Tumors for Which FISH Analysis Does Not Detect an Increase in EGFR Gene Copy Number , 2008, Annals of Surgical Oncology.

[47]  A. Jubb,et al.  Impact of vascular endothelial growth factor-A expression, thrombospondin-2 expression, and microvessel density on the treatment effect of bevacizumab in metastatic colorectal cancer. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[48]  L. Ellis,et al.  How well do we communicate with patients concerning adjuvant systemic therapy? A survey of 150 colorectal cancer survivors , 2007 .

[49]  R. Houlston,et al.  A prospective, blinded analysis of thymidylate synthase and p53 expression as prognostic markers in the adjuvant treatment of colorectal cancer. , 2006, Annals of oncology : official journal of the European Society for Medical Oncology.

[50]  C. Compton,et al.  Microsatellite instability predicts improved response to adjuvant therapy with irinotecan, 5-fluorouracil and leucovorin in stage III colon cancer. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[51]  E. Van Cutsem,et al.  KRAS wild-type state predicts survival and is associated to early radiological response in metastatic colorectal cancer treated with cetuximab. , 2008, Annals of oncology : official journal of the European Society for Medical Oncology.

[52]  S. Groshen,et al.  ERCC1 and thymidylate synthase mRNA levels predict survival for colorectal cancer patients receiving combination oxaliplatin and fluorouracil chemotherapy. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[53]  J. Baselga,et al.  Who will benefit from treatment against EGFR? , 2005, The Lancet. Oncology.

[54]  I. Ciernik,et al.  Radiation therapy and combined modality treatment of gastrointestinal carcinomas. , 2006, Cancer treatment reviews.

[55]  Daniel J Sargent,et al.  Tumor microsatellite-instability status as a predictor of benefit from fluorouracil-based adjuvant chemotherapy for colon cancer. , 2003, The New England journal of medicine.

[56]  S. Groshen,et al.  A multivariate analysis of genomic polymorphisms: prediction of clinical outcome to 5-FU/oxaliplatin combination chemotherapy in refractory colorectal cancer , 2004, British Journal of Cancer.

[57]  P. Jänne,et al.  EGFR, HER2 and Kras as predictive factors for cetuximab sensitivity in colorectal cancer , 2007 .

[58]  S. Kern,et al.  Genomic copy number changes affecting the thymidylate synthase (TYMS) gene in cancer: a model for patient classification to aid fluoropyrimidine therapy. , 2006, Cancer research.

[59]  K. Hirakawa,et al.  Expression of genes for 5-FU-metabolizing enzymes and response to irinotecan plus 5-FU-leucovorin in colorectal cancer. , 2006, Anticancer research.

[60]  H. Lenz,et al.  Pharmacogenomics and colorectal cancer. , 2004, Annals of oncology : official journal of the European Society for Medical Oncology.

[61]  A. V. van Kuilenburg.  Screening for Dihydropyrimidine Dehydrogenase Deficiency: To Do or Not To Do, That's The Question , 2006, Cancer investigation.

[62]  P. Catalano,et al.  Association between DNA Methylation and Shortened Survival in Patients with Advanced Colorectal Cancer Treated with 5-Fluorouracil–Based Chemotherapy , 2007, Clinical Cancer Research.

[63]  P. Danenberg.  Pharmacogenomics of thymidylate synthase in cancer treatment. , 2004, Frontiers in bioscience : a journal and virtual library.

[64]  B. Iacopetta,et al.  P53 alteration and microsatellite instability have predictive value for survival benefit from chemotherapy in stage III colorectal carcinoma. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.

[65]  B. Vainer,et al.  The prognostic significance of thymidylate synthase and dihydropyrimidine dehydrogenase in colorectal cancer of 303 patients adjuvantly treated with 5‐fluorouracil , 2007, International journal of cancer.

[66]  B. Giraudeau,et al.  ERCC1 Codon 118 Polymorphism Is a Predictive Factor for the Tumor Response to Oxaliplatin/5-Fluorouracil Combination Chemotherapy in Patients with Advanced Colorectal Cancer , 2005, Clinical Cancer Research.

[67]  Sharon Marsh,et al.  Thymidylate synthase pharmacogenetics , 2005, Investigational New Drugs.

[68]  P. Johnston,et al.  Predicting the outcome of chemotherapy for colorectal cancer. , 2006, Current opinion in pharmacology.

[69]  F. Hu,et al.  Association of dietary patterns with cancer recurrence and survival in patients with stage III colon cancer. , 2007, JAMA.

[70]  R. Diasio,et al.  Thymidine phosphorylase expression is associated with response to capecitabine plus irinotecan in patients with metastatic colorectal cancer. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[71]  Norman Wolmark,et al.  Prognostic and predictive roles of high-degree microsatellite instability in colon cancer: a National Cancer Institute-National Surgical Adjuvant Breast and Bowel Project Collaborative Study. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[72]  D. Sargent,et al.  Thymidylate Synthase Expression in Colon Carcinomas with Microsatellite Instability , 2006, Clinical Cancer Research.

[73]  A. Jubb,et al.  Predicting benefit from anti-angiogenic agents in malignancy , 2006, Nature Reviews Cancer.

[74]  L. Saltz.  Irinotecan in the Treatment of Colorectal Cancer , 2002 .